BRPI1005380A2 - colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio - Google Patents

colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio

Info

Publication number
BRPI1005380A2
BRPI1005380A2 BRPI1005380A BRPI1005380A BRPI1005380A2 BR PI1005380 A2 BRPI1005380 A2 BR PI1005380A2 BR PI1005380 A BRPI1005380 A BR PI1005380A BR PI1005380 A BRPI1005380 A BR PI1005380A BR PI1005380 A2 BRPI1005380 A2 BR PI1005380A2
Authority
BR
Brazil
Prior art keywords
difluprednate
eye drops
produce
macular edema
treat macular
Prior art date
Application number
BRPI1005380A
Other languages
English (en)
Inventor
Atsushi Okumura
Eriko Kirii
Hidetoshi Yamashita
Sachi Abe
Sakiko Goto
Teiko Yamamoto
Original Assignee
Univ Yamagata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamagata filed Critical Univ Yamagata
Publication of BRPI1005380A2 publication Critical patent/BRPI1005380A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1005380A 2009-07-14 2010-07-14 colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio BRPI1005380A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009165924 2009-07-14
PCT/JP2010/062289 WO2011007893A1 (en) 2009-07-14 2010-07-14 Eye drop with difluprednate for macular edema treatment

Publications (1)

Publication Number Publication Date
BRPI1005380A2 true BRPI1005380A2 (pt) 2016-02-10

Family

ID=42646370

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005380A BRPI1005380A2 (pt) 2009-07-14 2010-07-14 colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio

Country Status (13)

Country Link
US (3) US20110190250A1 (pt)
EP (1) EP2340014B1 (pt)
JP (1) JP5579079B2 (pt)
KR (1) KR101689847B1 (pt)
CN (3) CN107569494A (pt)
BR (1) BRPI1005380A2 (pt)
CA (1) CA2738151C (pt)
ES (1) ES2405779T3 (pt)
MX (1) MX2011005043A (pt)
PL (1) PL2340014T3 (pt)
RU (1) RU2572707C2 (pt)
TW (1) TW201105363A (pt)
WO (1) WO2011007893A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501492A1 (en) * 2011-01-14 2013-09-09 Sds Biotech Corp Agri-horticultural pest control compositions comprising 4-(3-butynyl)aminopyrimidine derivatives
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CN103130859B (zh) * 2011-11-30 2015-12-02 天津金耀集团有限公司 二氟泼尼酯晶型i及其制备方法
CN103130857A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯ⅱ晶型及其制备方法
EP2956144B1 (en) * 2013-02-15 2017-11-22 Senju Pharmaceutical Co., Ltd. Difluprednate emulsion composition containing zinc
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
JP2017528865A (ja) 2014-06-23 2017-09-28 ショット アクチエンゲゼルシャフトSchott AG 板状の別個の要素を有する蓄電システム、板状の別個の要素、並びにその製造方法、及びその使用
JP2018505515A (ja) 2014-12-01 2018-02-22 ショット アクチエンゲゼルシャフトSchott AG シート状の独立した部材を有する蓄電システム、独立したシート状の部材、その製造方法、およびその使用
WO2016196365A1 (en) * 2015-05-29 2016-12-08 Envisia Therapeutics, Inc. Implant for treatment of an ocular condition
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
CN108014172A (zh) * 2017-12-29 2018-05-11 广州仁恒医药科技股份有限公司 一种含有二氟泼尼酯的药物组合物及其制备方法
KR20210012346A (ko) 2019-07-25 2021-02-03 심낙범 미세먼지 눈꺼풀 세정스틱
WO2021050649A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
TW202607144A (zh) * 2024-07-16 2026-02-16 美商愛德維仁生物科技公司 使用編碼阿柏西普(aflibercept)之aav2變異體治療眼部新生血管性疾病的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556848A (en) 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
JP3781792B2 (ja) * 1993-12-27 2006-05-31 千寿製薬株式会社 ジフルプレドナート含有点眼用懸濁液剤
DE69807281T2 (de) * 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
MXPA05008561A (es) * 2003-02-20 2005-11-04 Alcon Inc Uso de esteroides para tratar personas que sufren de trastornos oculares.
US20050226814A1 (en) * 2004-04-13 2005-10-13 Bausch & Lomb Incorporated Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
WO2007025275A2 (en) 2005-08-25 2007-03-01 Psivida Inc. Control of induced elevated intraocular pressure
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor

Also Published As

Publication number Publication date
EP2340014A1 (en) 2011-07-06
KR101689847B1 (ko) 2016-12-26
MX2011005043A (es) 2011-06-01
RU2572707C2 (ru) 2016-01-20
US20150190340A1 (en) 2015-07-09
CN107569494A (zh) 2018-01-12
WO2011007893A1 (en) 2011-01-20
US9949926B2 (en) 2018-04-24
CN103705524A (zh) 2014-04-09
EP2340014B1 (en) 2013-04-24
US20110190250A1 (en) 2011-08-04
CN102170865A (zh) 2011-08-31
TW201105363A (en) 2011-02-16
CA2738151C (en) 2017-02-28
ES2405779T3 (es) 2013-06-03
JP2012533517A (ja) 2012-12-27
US10092514B2 (en) 2018-10-09
US20180133153A1 (en) 2018-05-17
JP5579079B2 (ja) 2014-08-27
CA2738151A1 (en) 2011-01-20
RU2011125640A (ru) 2013-08-20
PL2340014T3 (pl) 2013-09-30
KR20120040683A (ko) 2012-04-27

Similar Documents

Publication Publication Date Title
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BRPI0915476A2 (pt) dispositivo para tratar problemas respiratórios
CO6751293A2 (es) Derivados heterocíclicos novedosos y su uso en e tratamiento de trastornos neurológicos
BR112013022813A2 (pt) diaminocarbonitrila pirimidinas e diaminocarboxamida substituída, composições das mesmas e métodos de tratamento com as mesmas
CO6930321A2 (es) Curación de tejidos
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
EP2680923A4 (en) TISSUE TREATMENT AND MONITORING THROUGH THE USE OF ENERGY
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
CU20140025A7 (es) Pirimidinas anilladas sustituidas
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
HRP20160551T8 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
FI20095291L (fi) Kuitujen käsittely muovausta kestäväksi
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
HUE046581T2 (hu) PUFA-k alkalmazása bõrgyulladás kezelésére
BR112013013670A2 (pt) utilização de fluopiram para o controle de nematódeos em colheitas
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
BR112012003025A2 (pt) método de tratamento de males oculares.
BRPI1008253A2 (pt) Metoso para tratar biomassa
CO6910193A2 (es) Derivados de anilina, su preparación y su aplicación terapéutica
BR112013033138A2 (pt) componente para absorver e/ou transmitir forças mecânicas e/ou momentos, método de produção e uso de componente
HRP20181142T1 (hr) Pripravak za smanjenje apsorpcije masti iz prehrane

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]